Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Nuclear Size as Prognostic Determinant in Stage II and Stage III Colorectal Adenocarcinoma

ABDELBASET BUHMEIDA, ANNIKA ÅLGARS, RAIJA RISTAMÄKI, YRJÖ COLLAN, KARI SYRJÄNEN and SEPPO PYRHÖNEN
Anticancer Research January 2006, 26 (1B) 455-462;
ABDELBASET BUHMEIDA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: abuhme{at}utu.fi
ANNIKA ÅLGARS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RAIJA RISTAMÄKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YRJÖ COLLAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KARI SYRJÄNEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEPPO PYRHÖNEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The prognostic value of morphometric nuclear features was assessed in stage II and stage III colorectal cancer (CRC). Materials and Methods: Primary tumors from 123 CRC patients were analyzed using an image overlay drawing system for the following nuclear size features: area, perimeter, diameter and form features. Results: The nuclear area (NA) was significantly different in tumors at different localizations (p=0.029). A large NA was a significant predictor of recurrent disease, with overall response (OR) 3.09 (1.37-6.95) (p=0.006). The NA was significantly larger in recurrent cases (106.3 μm2) than in non-recurrent ones (96.6 μm2) (p=0.007) and was a significant predictor of disease-free survival (DFS) in univariate (Kaplan-Meier) analysis (log-rank p=0.0239). However, lymph node involvement was the most powerful predictor of DFS in multivariate analysis, with OR 3.371 (95%CI 1.17-9.65) (p=0.024) and disease recurrence the only independent predictor of disease-specific survival (DSS), with OR 48.4 (95%CI 6.30-371.73). Conclusion: Quantitative measurement of the NA seems to accurately discriminate the patients, among stage II and III colorectal cancer, who are likely to develop disease recurrence. Image morphometry seems to be a useful adjunct tool in examining the subgroup of lymph node-negative patients to predict the risk of disease recurrence and indications for adjuvant therapy.

  • Nuclear morphometry
  • nuclear area
  • colorectal cancer
  • adjuvant therapy

Footnotes

  • Received November 14, 2005.
  • Accepted November 25, 2005.
  • Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 26, Issue 1B
January-February 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nuclear Size as Prognostic Determinant in Stage II and Stage III Colorectal Adenocarcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
15 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Nuclear Size as Prognostic Determinant in Stage II and Stage III Colorectal Adenocarcinoma
ABDELBASET BUHMEIDA, ANNIKA ÅLGARS, RAIJA RISTAMÄKI, YRJÖ COLLAN, KARI SYRJÄNEN, SEPPO PYRHÖNEN
Anticancer Research Jan 2006, 26 (1B) 455-462;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Nuclear Size as Prognostic Determinant in Stage II and Stage III Colorectal Adenocarcinoma
ABDELBASET BUHMEIDA, ANNIKA ÅLGARS, RAIJA RISTAMÄKI, YRJÖ COLLAN, KARI SYRJÄNEN, SEPPO PYRHÖNEN
Anticancer Research Jan 2006, 26 (1B) 455-462;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Prognostic value of proliferation, PD-L1 and nuclear size in patients with superior sulcus tumours treated with chemoradiotherapy and surgery
  • DNA Image Cytometry Predicts Disease Outcome in Stage II Colorectal Carcinoma
  • Google Scholar

More in this TOC Section

  • Evaluation of the Validity of Pancreatoduodenectomy for Elderly Patients With Ampullary Carcinoma from the Perspective of Nutritional Status at Recurrence
  • Real-world Analysis of Urinary Protein-to-Creatinine Ratio and Blood Pressure in Lenvatinib Therapy
  • Expression of Vascular Endothelial Growth Factor A in Gallbladder Cancer Cells: A Clinicopathological Study
Show more Clinical Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire